Skip to main content
SIU Annual Conference Main banner
 
Presentation Icons
Surgery Day
Surgery Day
Bench-to-Bedside
Bench-to-Bedside
SIU@U
SIU@U

    Session: Luncheon Symposium: HER2-Targeted Antibody-Drug Conjugates in Metastatic Bladder Cancer: A New Era of Precision Oncology

    B2B-02: Panel Discussion

    Friday, October 31, 2025
    12:25 - 12:40 GMT+0

      Panelist(s)

    • Kilian Martin Gust

      Medical University of Vienna, Department of Urology
      Austria, Austria

    • Daniele Raggi

      Consultant Medical Oncologist
      The Royal Marsden Foundation Trust, United Kingdom

    Learning Objectives :

    At the end of this session, attendees should be able to:
    • Understand the biology of HER2 alterations in urothelial carcinoma.
    • Recall the mechanism of action, design and applications of ADCs in metastatic bladder cancer.
    • Recognize the role of HER2 as a therapeutic target in urothelial carcinoma.
    • Analyze the current and emerging clinical data on HER2-targeted ADCs.